Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Agios Pharma (AGIO – Research Report), Trupanion (TRUP – Research Report) and Kymera Therapeutics (KYMR – Research Report).
Trupanion (TRUP)
In a report released yesterday, Joshua Shanker from Bank of America Securities reiterated a Hold rating on Trupanion, with a price target of $35.00. The company’s shares closed last Thursday at $29.24.
According to TipRanks.com, Shanker is a 4-star analyst with an average return of
Trupanion has an analyst consensus of Moderate Buy, with a price target consensus of $37.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AGIO:
- Agios Reports Business Highlights and Second Quarter 2023 Financial Results
- Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
- Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
- Agios says Phase 2 portion of RISE UP study meets primary efficacy endpoint
- Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
